Form 4: Arcus Biosciences Exec Sells Shares Under 10b5-1 Plan

Arcus Biosciences President Juan C. Jaen reported the sale of company stock totaling over 31,000 shares across multiple transactions executed between June 22 and June 24, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc., reported transactions involving the sale of common stock.
• These sales occurred between June 22, 2026, and June 24, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on February 27, 2026.
• A total of 9,236 shares were sold on June 22, 2026, at a weighted average price of $27.0313.
• On June 23, 2026, 14,067 shares were sold at a weighted average price of $27.6875, and an additional 1,697 shares were sold at a weighted average price of $28.0612.
• On June 24, 2026, 6,431 shares were sold at a weighted average price of $29.6595.
• Following these transactions, Jaen beneficially owns 890,809 shares, with 378,291 of these being unvested RSUs.
• The filing also notes the purchase of 1,279 shares on May 31, 2026, through the Company's Employee Stock Purchase Plan.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a top executive, despite the use of a 10b5-1 plan.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider-trading-related transactions.
• The reporting person acquired additional shares through the Employee Stock Purchase Plan, showing continued investment in the company.

Negatives

• Significant sale of company stock by a key executive (President).
• The total value of shares sold across the reported dates is substantial, though specific total value is not explicitly stated, it involves over 31,000 shares.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The weighted average prices indicate a range of sales, with some occurring at lower prices than others, which could be a point of concern for investors tracking the executive's exit price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives looking to diversify holdings or meet financial obligations. However, the volume and timing relative to company news can influence market perception.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially impacting stock price, although the 10b5-1 plan mitigates concerns about non-public information.
• Employees: May be influenced by executive trading activity, though the purchase through the ESPP shows continued employee participation.
• Management: Demonstrates adherence to regulatory requirements for reporting ownership changes.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The company may provide further updates on executive holdings or transactions in future filings.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Arcus Biosciences, RCUS, Stock Sale, Executive Compensation, Beneficial Ownership, Juan C. Jaen